Avadel Pharmaceuticals Sees Robust Uptake For Its Newly Approved Sleep Disorder Drug

  • By Grand News Network
  • |
  • November 8, 2023

Avadel Pharmaceuticals plc (NASDAQ: AVDL) recognized $7.0 million in net product revenue for Q3. Net product revenue consists of Lumryz product sales, launched in the U.S. in June. Analysts estimated revenues of $5.09 million.

In May, the FDA granted final approval to Lumryz, an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for cataplexy or excessive daytime sleepiness (EDS) in ...

Full story available on

Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.

Disclaimer Press Release Banner

More Stories